A possible role for the endocannabinoid system in the neurobiology of depression

Clinical Practice and Epidemiology in Mental Health

Volumn 3, Issue , 2007, Pages

  Serra, Gino ^a   Fratta, Walter ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ANANDAMIDE; ANTIDEPRESSANT AGENT; ARACHIDONYL 2 CHLOROETHYLAMIDE; AVE 1625; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; FLUOXETINE; IMIPRAMINE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; NEUROLEPTIC AGENT; OLEAMIDE; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SR 141416A; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

CELL PROLIFERATION; DEPRESSION; DISEASE PREDISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ELECTROCONVULSIVE THERAPY; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MESOLIMBIC DOPAMINERGIC SYSTEM; MONOAMINERGIC SYSTEM; NERVE CELL DIFFERENTIATION; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; REVIEW; SUICIDAL IDEATION;

EID: 37849029289     PISSN: 17450179     EISSN: None     Source Type: Journal    
DOI: 10.1186/1745-0179-3-25     Document Type: Review

References (102)

1. Schildkraut JJ The catecholamine hypothesis of affective disorders: A review of supporting evidence Am J Psychiatry 1965, 122:509-522 5319766
2. Baldessarini RJ Drug therapy of depression and anxiety disorders Goodmanand Gilman's The Pharmacological Basis of Therapeutics McGRAW-Hill Laurence LB, John SL, Keith LP 11 2006:429-459
3. Delgado PI Depression: The case for a monoamine deficiency J Clin Psychiatry 2000, 61(Suppl 6):7-11 10775018
4. Heninger GR Delgado PI Charney DS The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans Pharmacopsychiatry 1996, 29(1):2-11 8852528
5. Hirschfeld RM History and evolution of the monoamine hypothesis of depression J Clin Psychiatry 2000, 61(Suppl 6):4-6 10775017
6. Charney DS Monoamine dysfunction and the pathophysiology and treatment of depression J Clin Psychiatry 1988, 59(Suppl 14):11-14
7. Garver DL Davis JM Biogenic amine hypothesis of affective disorders Life Sci 1979, 24:383-394 10.1016/0024-3205(79)90208-X 372718
8. Sugrue MF Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning Pharmacol Ther 1983, 21:1-33 10.1016/0163-7258(83)90065-7 6312466
9. D'Aquila PS Collu M Gessa GL Serra G The role of dopamine in the mechanism of action of antidepressant drugs Eur J Phamacol 2000 29,405(1-3):365-373 10.1016/S0014-2999(00)00566-5
10. Nestler EJ Carlezon W The mesolimbic dopamine reward circuit in depression Biol Psychiatry 2006, 59(12):1151-1159 10.1016/ j.biopsych.2005.09.018 16566899
11. Schatzberg AF Rothscild AJ Langlais PJ Bird ED Cole JO A corticosteroid/ dopamine hypothesis for psychotic depression and related states J Psychiatr Res 1985, 19(1):57-64 10.1016/0022-3956(85)90068-8 2859366
12. Macqueen GM Campbell S Mcewen BS Macdonald K Amano S Joffe RT Nahmias C Young LT Course of illness, hippocampal function, and hippocampal volume in major depression PNAS 2003, 100(3):1387-1392 298782 12552118 10.1073/ pnas.0337481100
13. Videbech P Ravnkilde B Hippocampal volume and depression. A meta-analysis of MRI studies Am J Psychiatry 2004, 161(11):1957-1966 10.1176/appi.ajp.161.11.1957 15514393
14. Sheline YI Gado Mokhtar H Kroemer HC Untreated depression and hippocampal volume loss Am J Psychiatry 2003, 160:1516-1518 10.1176/ appi.ajp.160.8.1516 12900317
15. Malberg JE Implication of adult hippocampal neurogenesis in antidepressant action J Psychiatry Neurosci 2004, 29(3):196-205 400689 15173896
16. Santarelli L Saxe M Gross C Surget A Battaglia F Dulawa S Weisstaub N Lee J Duman RS Arancio O Belzung C Hen R Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 2003, 8301(5634):805-809 10.1126/science.1083328
17. Warner-Schmidt JL Duman RS Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment Hippocampus 2006, 16(3):239-249 10.1002/hipo.20156 16425236
18. Vaida VA Duman RS Depression: emerging insights from neurobiology Br Med Bull 2001, 57:61-79 10.1093/bmb/57.1.61 11719924
19. Russo-Neustadt AA Chen MJ Brain-derived neurotrophic factor and antidepressant activity Curr Pharm Des 2005, 11(12):1495-1510 10.2174/ 1381612053764788 15892658
20. Rogoz Z Legutko B Combined treatment with imipramine and metyrapone induces hippocampal and cortical Brain-derived neurotrophic factor gene expression in rats Pharmacological Reports 2005, 57:840-844 16382205
21. Nibuya M Morinobu S Duman RS Regulation of BDNF and Trkb mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatment J Neurosci 1995, 15(11):7539-7547 7472505
22. Rasmusson AM Shi L Duman RS Down-regulation of BDNF mRNA in the hippocampal dentate gyrus after re-exposure to cues previously associated with foot shock Neuropsychopharmacology 2002, 27:133-142 10.1016/S0893-133X(02)00286-5 12093587
23. Shirayama Y Chen AC Nakagawa S Russell DS Duman RS Brain-derived neurotrophic factor produces antidepressant effects in behavioural models of depression J Neurosci 2002, 22(8):3251-3261 11943826
24. D'sa C Eisch AJ Bolger GB Duman RS Differential expression and regulation of the cAMP selective phosphodiesterase type 4a splice variants in rat brain by chronic antidepressant administration Eur J Neurosci 2005, 22(6):1463-1475 10.1111/j.1460-9568.2005.04321.x 16190900
25. Blendy JA The role of CREB in depression and antidepressant treatment Biol Psychiatry 2006, 59(12):1144-1150 10.1016/j.biopsych.2005.11.003 16457782
26. Duman RS Heninger GR Nestler J A molecular and cellular theory of depression Arch Gen Psychiatry 1997, 54:597-606 9236543
27. Young T Bakish D Beaulieu S The neurobiology of treatment response to antidepressants and mood stabilizing medications J Psychiatry Neurosci 2002, 27(4):260-265 161660 12174735
28. Holboer F The corticosteroid hypothesis of depression Neuropsychopharmacology 2000, 23(5):477-501 10.1016/ S0893-133X(00)00159-7 11027914
29. Tichomirova MA Keck ME Schneider HJ Paez-Pereda M Renner U Holsboer F Stalla GK Endocrine disturbances in depression J Endocrinol Invest 2005, 28(1):89-99 15816377
30. Sapolsky RM Glucocorticioids and hippocampal atrophy in neuropsychiatric disorders Arch Gen Psychiatry 2000, 57:925-935 10.1001/ archpsyc.57.10.925 11015810
31. Haynes LE Barber D Mitchel IJ Chronic antidepressants medication attenuates dexamethasone-induced neuronal death and sublethal neuronal demage in the hippocampus and striatum Brain Res 2004, 12,1026(2):157-167 10.1016/j.brainres.2004.05.117
32. Wong EY Hrrbert J Raised circulating corticosterone inhibits neuronal differentiation of progenitor cells in the adult hippocampus Neuroscience 2006, 137(1):83-92 10.1016/j.neuroscience.2005.08.073 16289354
33. Ridder S Chourbaji S Hellweg R Urani AI Zacher C Schmid W Zink M Hornagl H Flor H Henn FA Schutz G Gass P Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions The Journal of Neuroscience 2005, 25(26):6243-6250 10.1523/JNEUROSCI.0736-05.2005 15987954
34. Starkman MN Giordani B Gebarski SS Berent S Schork MA Schteingart DE Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease Biol Psychiatry 1999, 15,46(12):1595-1602 10.1016/S0006-3223(99)00203-6
35. Devane WA Dysarz FA Johnson M Melvin LS Howlett AC Determination and characterization of a cannabinoid receptor in rat brain Molecular Pharmacology 1988, 34:605-613 2848184
36. Howlett AC Bidaut-Russel M Devane WA Melvin LS Johnsonand MR Herkenham M The cannabinoid receptor: biochemical, anatomical and behavioural characterization Trends In Neurosci 1990, 13:420-423 10.1016/ 0166-2236(90)90124-S
37. Munro S Thomas KL Au-Shaar M Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365:61-65 10.1038/365061a0 7689702
38. Howlett AC Barth F Bonner TI Cabral G Casellas P Devane WA Felder CC Herkenham M Mackie K Martin BR Mechoulam R Pertwee RG International Union of Pharmachology XXVII Classification of Cannabinoid Receptors Pharmacol Rev 2002, 54(29):161-202 10.1124/pr.54.2.161 12037135
39. Herkenham M Lynnm AB Johnson R Melvin LS Decosta BR Rice KC Characterization and localization of cannabinoid receptors in rat brain: a quantitative invitro autoradiographic study J of Neurosci 1991, 33:263 583
40. Piomelli D The molecular logic of endocannabinoid signalling Nature Reviews Neuroscience 2003, 4:873-884 10.1038/nrn1247 14595399
41. Gong JP Onaivi ES Ishiguro H Liu QR Tagliaferro PA Brusco A Uhi GR Cannabinoid CB2 receptors: immunoistochemical localization in rat brain Brain Res 2006, 1071(1):10-23 10.1016/j.brainres.2005.11.035 16472786
42. Onaivi ES Ishiguro H Sejal P Meozzi PA Myers L Tagliaferro PA Hope B Leonard CM Uhi GR Brusco A Gardner E Methods to study the behavioural effects and expression of CB2 cannabinoid receptor and its gene transcripts in the in the chronic mild stress model of depression Methods Mol Med 2006, 123:291-298 16506415
43. Demuth DG Molleman A Cannabinoid signalling Life Sci 2006, 78(6):549-563 10.1016/j.lfs.2005.05.055 16109430
44. Devane WA Hanus L Breuer A Pertwee RG Stevenson LA Griffin G Gibson D Mandelbaum A Etinger A Mechoulam R Isolation and structure of a brain constituent that binds to the cannabinoid receptors Science 1992, 258:1946-1949 10.1126/science.1470919 1470919
45. Mechoulam R Ben-Shabat S Hanus L Ligumsky M Kaminski NE Shatz AR Gopher A Almog S Martin BR Compton DR Identification of an endogenous 2Monoglyceride, present in canine gut, that binds to cannabinoid receptors Biochemical Pharmacology 1995, 50:83-90 10.1016/ 0006-2952(95)00109-D 7605349
46. Sugiura T Kondo S Sukagawa A Nakane S Shinoda A Itoh K Yamashitaand A Waku K 2Arachidonoylglycerol, a possible endogenous cannabinoid receptor ligand in brain Biochemistry Biophisics Research Communications 1995, 215:89-97 10.1006/bbrc.1995.2437
47. Stella N Schweitzer P Piomelli D A second endogenous cannabinoid that modulates long-term potentiation Nature 1997, 388:773-778 10.1038/42015 9285589
48. Okamoto Y Morishita J Tsuboi K Tonai T Ueda N Molecular characterization of a phospholipase D generating anandamide and its congeners Journal of Biological Chemistry 2004, 279:5298-5305 10.1074/jbc.M306642200 14634025
49. Giuffrida A Beltramo M Piomelli D Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology J of Pharmacol and Exp Therap 2001, 298:7-14
50. Beltramo M Stella N Calignano A Lin SY Makriyannis A Piomelli D Functional role of high-affinity anandamide transport, as revealed by selective inhibition Science 1997, 277:1094-1097 10.1126/ science.277.5329.1094 9262477
51. Cravatt BF Giang DK Mayfield SP Borger DL Lerner RA Gilula NB Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides Nature 1996, 384:83-87 10.1038/384083a0 8900284
52. Dinh TP Carpenter D Leslie FM Freund TF Katona I Sensi SL Kathuria S Piomelli D Brain monoglyceride lipase participating in endocannabinoid inactivation PNAS 2002, 99:10819-10824 125056 12136125 10.1073/ pnas.152334899
53. Rodriguez De Fonseca F Del Arco I Bermudez-Silva FJ Bilbao A Cippitell A Navarro M The endocannabinoid system: physiology and pharmacology Alcohol and Alcoholism 2005, 40(1):2-14 10.1093/alcalc/agh110
54. Fattore L Deiana S Spano SM Cossu G Fadda P Scherma M Fratta W Endocannabinoid system and opioid addiction: behavioural aspects Pharmacol Biochem and Behavior 2005, 81:343-359 10.1016/j.pbb.2005.01.031
55. Martin M Ledent C Parmentier M Maldonado R Valverde O Involvement of CB1 cannabinoid receptors In emotional behaviour Psychopharmacology 2002, 159:379-387 10.1007/s00213-001-0946-5 11823890
56. Maldonado R Valverde O Berrendero F Involvement of the endocannabinoid system in drug addiction Trends Neurosci 2006, 29(4):225-232 10.1016/ j.tins.2006.01.008 16483675
57. Valverde O Participation of the cannabinoid system in the regulation of emotional-like behaviour Curr Pharm Des 2005, 11(26):3421-3429 10.2174/ 138161205774370780 16250845
58. Viveros MP Marco EM File SE Endocannabinoid system and stress and anxiety responses Pharmacology Biochemistry and Behavior 2005, 81(2):331-342 10.1016/j.pbb.2005.01.029
59. Hill MN Gorzalka BB Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behavioral Pharmacology 2005, 16:333-352 10.1097/00008877-200509000-00006
60. Witkin JM Tzavara ET Davis RJ Lia X Nomikos GG A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders Trends In Pharmacological Sciences 2005, 26(12):609-617 10.1016/ j.tips.2005.10.006 16260047
61. Witkin JM Tzavara ET Nomikos GG A role for cannabinoid CB1 receptors in mood and anxiety disorders Behavioral Pharmacology 2005, 16:315-331 10.1097/00008877-200509000-00005
62. Hill MN Gorzalka BB Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test European Neuropsychopharmacology 2005, 15:593-599 10.1016/j.euroneuro.2005.03.003 15916883
63. Gobbi G Bambico FR Mangieri R Bortolato M Campolongo P Solinas M Cassano T Morgese MG Debonnel G Duranti A Tontini A Tarzia G Mor M Trezza V Goldberg SR Cuomo V Piomelli D Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis PNAS 2005, 102(51):18620-18625 1317988 16352709 10.1073/ pnas.0509591102
64. Bortolato M Mangieri RA Fu J Kim JH Arguello O Duranti A Tontini A Mor M Tarzia G Piomelli D Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress Biol Psychiatry 2007 17511970
65. Naidu PS Varvel SA Ahn K Cravatt BF Martin BR Lichtman AH Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality Psychopharmacology 2007, 192(1):65-70 10.1007/s00213-006-0689-4
66. Rutkowska M Jachimezuk O Antidepressant-like properties of ACEA(Arachidonyl-2-Chloroethylamide), the selective agonist of CB1 receptors Acta Pol Pharm 2004, 61(2):165-167 15493300
67. Jiang W Zhang Y Xiao L Van Cleemput J Ji SP Bai G Zhang X Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects J Clin Invest 2005, 115:3104-3116 1253627 16224541 10.1172/JCI25509
68. Shearman LP Rosko KM Fleischer R Wang J Xu S Tong XS Rocha BA Antidepressant-like and anoretic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice Behavioral Pharmacology 2003, 14:573-582 10.1097/00008877-200312000-00001
69. Tzavara ET Davis RJ Perry RW Li X Salhoff C Bymaster FP Witkinand JM Nomikos GG The CB1 receptor antagonist SR141716 selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions British Journal of Pharmacol 2003, 138:544-553 10.1038/sj.bjp.0705100
70. Griebel G Stemmelin J Scatton B Effects of the cannabinod CB1 receptor antagonist Rimonabant in models of emotional reactivity in rodents Biol Psychiatry 2005, 57:261-267 10.1016/j.biopsych.2004.10.032 15691527
71. Pratt J Roux M Stutzmann JM Piot-Grosjean O Benavides J Effect of AVE1625, a novel cannabinoid CB1 receptor antagonist, in models of aggression and depression. Program No 653.16 2005 (Abstract) Viewer/ Itinerary Planner Washington Dc. Society For Neuroscience
72. Jin K Xie L Kim SH Parmentier-Batteur S Sun Y Mao X Childs J Greenberg DA Defective adult neurogenesis in CB1 cannabinoid receptor Knockout mice Mol Pharmacol 2004, 66(2):204-208 10.1124/mol.66.2.204 15266010
73. Bass CE Griffin G Grier M Mahadevan A Razdan RK Martin BR SR141716A-induced stimulation of locomotor activity. A structure-activity relationship study Pharmacol Biochem Behav 2002, 74(1):31-40 10.1016/S0091-3057(02)00945-0 12376150
74. Rodriguez de Fonseca F Del Arco I Martin-Calderon JL Gorriti MA Navarro M Role of endogenous cannabinoid system in the regulation of motor activity Neurobiol Dis 1998, 5(6):483-501 10.1006/nbdi.1998.0217 9974180
75. Carai MA Colombo G Maccioni P Gessa GL Efficacy of Rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data CNS Drug Rev 2006, 12(2):91-99 10.1111/j.1527-3458.2006.00091.x 16958983
76. Hill MN Patel S Carrier EJ Rademaker DJ Ormerod BK Hillard CJ Gorzalka BB Downregulation of endocannabinoid signalling in the hippocampus following chronic unpredictable stress Neuropsychopharmacology 2005, 30(3):508-515 10.1038/sj.npp.1300601 15525997
77. Oliva JM Uriguen L Perz-Rial S Manzanares J Time course of opioid and cannabinoid gene transcription: Alterations induced by repeated administration with fluoxetine in the rat brain Neuropharmacology 2005, 49(5):618-626 15936043
78. Hill MN Carrier EJ Ho WV Meier S Hillard CJ Gorzalka BB Phamacologically distinct antidepressants differentially regulate the endocannabinoid system 15th Annual Symposium on the cannabinoids, (Abstract), Clearwater Beach, Florida, USA June, 24-27, 2005
79. Hill MH Ho WV Carrier EJ Hillard CJ Gorzalka BB Differential regulation of the endocannabinoid system following treatment with pharmacologically distinct antidepressants. Program No 447,4 2005 (Abstract) Viewer/ Itinerary Planner Washington Dc:SOciety For Neuroscience
80. Pazos A Valdizanand E Mato S The antidepressant fluoxetine increases both the costitutive and the agonist-dependent functionality of brain CB1 receptors. Program No 447.7 2005 (Abstract) Viewer/Itinerary Planner Washington Dc:SOciety For Neuroscience
81. Hill MN Ho WS Sinopoli KJ Viau V Hillard CJ Gorzalka BB Involvement of endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypotalamic-pituitary-adrenal axis Neuropsychopharmacology 2006, 31(12):2591-2599 10.1038/sj.npp.1301092 16710317
82. Gobshtis N Ben-Shabat S Fride E Antidepressant-induced undesiderable weight gain: Prevention with rimonabant without interference with behavioral effectiveness Eur J Pharmacol 2007, 554(2-3):155-163 10.1016/ j.ejphar.2006.10.028 17116301
83. Hill MN Barr AM Ho WS Carrier EJ Gorzalka BB Hillard CJ Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity J Neurochemistry 2007, 103(1):47-56 10.1111/j.1471-4159.2007.04713.x
84. Despres JP Golay A Sjostrom L Rimonabant in Obesity-Lipids Study Group: effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia N Engl J Med 2005, 353(20):2121-2134 10.1056/ NEJMoa044537 16291982
85. Gelfand Cannon CP Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors J Am Coll Cardiol 2006 16,47(10):1919-1926 10.1016/j.jacc.2005.12.067
86. Food and Drug Administration (FDA)'s Endocrinologic and Metabolic Drugs Advisory Committee: June 13, 2007
87. European Medicines Agency (EMEA)'s Committee for Medicinal Products for Human use (CHMP):JUly 19, 2007
88. Ashton CH Moore P Gallangher P Young AH Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential Journal of Psychopharmacology 2005, 19(3):293-300 10.1177/ 0269881105051541 15888515
89. Grinspoon L Balkar JB The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research J Psychoactive Drugs 1998, 30:171-177 9692379
90. Gruber AJ Pope HG Brown ME Do patients use marijuana as an antidepressant? Depression 1996, 4:77-80 10.1002/ (SICI)1522-7162(1996)4:2<77::AID-DEPR7>3.0.CO;2-C 9160645
91. Henquet C Krabbendam L Degraaf R Ten Have M Van Os J Cannabis use and expression of mania in the general population J Affect Disord 2006, 95(1-3):103-110 10.1016/j.jad.2006.05.002 16793142
92. Nunez Dominguez LA Cannabis use and bipolar disorder Bipolar Disord 2006, 5(2):60-62
93. Johns A The psychiatric effects of cannabis Br J Psychiatry 2001, 178:116-122 10.1192/bjp.178.2.116 11157424
94. Cassidy F Ahearn EP Carrol BJ Substance abuse in bipolar disorders Bipolar Disord 2001, 3:181-188 10.1034/j.1399-5618.2001.30403.x 11552957
95. Dalton EJ Cate-Carter TD Mundo E Parikh SV Kennedy JL Suicide risk in bipolar patients: the role of co-morbid substance use disorders Bipolar Disord 2003, 3:58-61 10.1034/j.1399-5618.2003.00017.x
96. Hungund BL Vinod KY Kassir SA Basavarajappa BS Yalamanchili R Cooper TB Mann JJ Arango V Up-regulation of CB1 receptors and agonist-stimulated (35s)GTPgs binding in the prefrontal cortex of depressed suicide victims Molecular Psychiatry 2004, 9:184-190 10.1038/sj.mp.4001376 14966476
97. Vinod KI Arango V Xie S Kassir SA Mann JJ Cooper TB Hungund BL Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signalling in the prefrontal cortex of alcoholic suicide victims Biol Psychiatry 2005, 57:480-486 10.1016/j.biopsych.2004.11.033 15737662
98. Vinod KY Hungund BL Role of endocannabinoid system in depression and suicide Trends Pharmacol Sci 2006, 27(10):539-545 10.1016/ j.tips.2006.08.006 16919786
99. Hill MN Miller GE Carrier EJ Ho WS Gorzalka BB Hillard CJ Dynamic regulation of serum endocannabinoid content in affective disease and following social stress in humans (Abstract)16th Annual Symposium On The Endocannabinoids Tihany, Hungary June 24-28, 2006
100. Miller GE Hill MN Ho WS Gorzalka BB Hillard CJ Bidirectional alterations in serum endocannabinoids in minor and major depression. Program No 107.3 2005 (Abstract) Viewer/Itinerary Planner Washington, D C:SOciety For Neuroscience
101. Koethe D Lienos IC Dulay JR Hoyer C Torrey EF Leweke FM Weis S Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression J Neural Transm 2007, 114(8):1055-1068 10.1007/s00702-007-0660-5 17370106
102. Madsen MV Peacock L Werge T Andersen MB Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys J Psychopharmacol 2006, 20(5):622-628 10.1177/0269881106063816 16533866